A laboratory contract may promise that one party “owns all data,” but that phrase rarely answers the questions that matter when a physician group, reference laboratory, collection partner or technology company stops working with another party. Specimens have custody and handling requirements; patient information implicates HIPAA access and disclosure rules; analytical results may reside in multiple designated record sets; and the contract governs business responsibilities within applicable law. A single intellectual-property clause cannot resolve all of those issues. For a related vendor-contract issue, see BOLO’s discussion of laboratory consulting deliverables and conflicts.
Identify every role in the testing chain
Start by mapping the ordering practitioner, collecting entity, testing laboratory, reference laboratory, laboratory information system vendor, courier and party receiving results. Each may have distinct records, performance duties and limitations on use. A specimen collected in a clinic may later be accessioned by a laboratory, sent to a reference laboratory and processed on equipment whose software retains audit trails. The final result may appear in the ordering EHR and in separate lab systems.
Contracts should state who receives each specimen, who verifies identifiers and integrity, who documents rejections, who may subcontract testing and who handles loss or delay. Regulatory obligations cannot be shifted away simply by writing that one party “assumes full compliance responsibility.” The actual certification, provider roles, enrollment and legal duties must be evaluated.
Custody of the physical specimen is a separate question
A contract should address acceptable collection containers, storage conditions, transport temperature where relevant, chain-of-custody records, specimen retention, residual specimen disposal, and whether secondary testing may occur. Depending on test type, CLIA, state rules, accreditor standards and other requirements can prescribe record or material retention. A blanket statement that every specimen must be kept for the same number of years is unreliable.
When an agreement ends, parties need a plan for pending specimens and tests. Determine whether an unfinished test is completed by the existing laboratory, transferred using a lawful protocol or canceled with appropriate communication. Define who notifies the ordering clinician and who documents the reason. No handoff should compromise patient safety or quality systems merely to satisfy a commercial closing date.
Patients have rights that neither party can contract away
HHS explains that individuals generally have a HIPAA right to access protected health information in a designated record set held by a covered clinical laboratory. Depending on what the laboratory maintains, that may include completed reports, underlying data, orders, ordering-provider information and billing or insurance information. Access rules are not limited to the glossy report delivered to a physician. HHS also distinguishes a completed test report from an unfinished report, while recognizing other accessible records may already exist.
Accordingly, an agreement that gives a software vendor an exclusive claim over “all patient data” needs close examination. Contractual ownership language cannot erase legally applicable patient access and retention duties. Identify who answers access requests, which systems hold responsive information and how requests are escalated when data reside with a subcontractor.
Who can use de-identified and aggregate information?
Laboratories and their vendors may want to use aggregate throughput measures, quality metrics, algorithmic performance data or de-identified datasets. The agreement should distinguish truly de-identified information under an applicable HIPAA method from limited datasets and ordinary PHI. Determine whether other restrictions apply, including consent requirements, research rules, professional obligations, third-party licenses or state law. The parties should specify whether secondary use is allowed, whether further transfer is permitted and what security obligations survive termination.
Marketing materials sometimes describe all information as “anonymized” without explaining the method or residual risks. A contract should not rely on vague terminology where legal compliance depends on whether identifiers can be linked to individuals.
Map the economics and the compliance risk together
Many laboratory contracts involve equipment, software, management, processing services, courier arrangements, consultation, marketing or referral relationships. The fee structure should describe exactly which legitimate services are provided, who is paid, what counts as performance and what costs or offsets apply. Where compensation or services interact with referrals for federally reimbursable items, separate review under the Anti-Kickback Statute or other applicable law may be necessary. The existence of a written fair-market-value fee is relevant to some analyses but does not independently establish compliance.
Providers and laboratories should also decide who responds when an audit disputes medical necessity, an order is missing or the payer alleges a systemic billing error. Allocate access to claims histories, test menus, accession logs and clinician-facing communications without creating barriers to lawful preservation and response.
Avoid the most common exit failures
Before a transition, export a reliable index of accession numbers, patient and ordering-provider identifiers as legally appropriate, specimen status, results, amended reports, rejected specimens, pending confirmatory tests, billing status and records under a hold. Identify which source system is authoritative for each field. Assign a responsible party and deadlines for final result delivery, appeals and amended reports after termination. Put a dispute-escalation process in writing before access to any system is disconnected.
A useful transition agreement includes data dictionaries and formats, limited ongoing access, confidentiality obligations, permitted destruction when lawful, and cooperation in correcting a clinically significant result. It also accounts for records the entity must retain even after contract termination.
A pre-signature exercise
Ask what would happen if a laboratory lost system access midweek, a treating physician requested an old result, a patient requested the underlying data, or a Medicare auditor asked for contemporaneous orders three years later. If the contract cannot answer who acts, within what time, and from what system, the operational risk is not allocated clearly.
BOLO Health Law advises laboratory and diagnostic businesses on laboratory contracts and regulatory questions, healthcare vendor agreements and audit-readiness review.
Primary authorities
HHS: Laboratory Patient Access Beyond Test Reports; HHS: Access to Reports Not Yet Complete; HHS: Patient Access and CLIA.
Attorney advertising. General legal information reviewed October 18, 2026, for publication October 19, 2026. The applicable rules, contract terms, and deadlines depend on the particular facts. This article is not legal advice, does not predict a result, and does not establish an attorney-client relationship. BOLO Health Law is a New Jersey law firm; representation is subject to conflicts, admission, and engagement terms.